

In a head-to-head study,
Simparica Trio® outperformed
NexGard® PLUS against the drug
resistant heartworm isolate ZoeLA.¹



SimparicaTRIO
(sarolaner, moxidectin, and pyrantel
chewable tablets)

Resistant heartworm study results




Six monthly doses
of Simparica Trio
**protected more dogs
from infection*** with
the resistant heartworm
isolate ZoeLA compared
to NexGard PLUS

Simparica Trio was more effective¹



Simparica Trio-treated
dogs had significantly
lower heartworm counts
than Nexgard PLUS-treated
dogs[†], and Simparica Trio
demonstrated **99.5%
efficacy[‡]**

Optimized dose



Simparica Trio delivers a
higher moxidectin dose
(24-48 µg/kg) than
NexGard® PLUS (12-24
µg/kg), which was **more
effective against resistant
heartworm isolates¹⁻³**

Reduce heartworm disease transmission risk



In this study, **no dogs
(0/8) in the Simparica
Trio-treated group
became microfilaremic**
vs 12.5% of dogs (1/8) in
the NexGard PLUS group

PROTECTION MADE SIMPLE

In studies to support FDA approval, 1 dose of Simparica Trio provided 100% protection against heartworm disease. The NexGard PLUS label states that treatment with fewer than 6 monthly doses after the last exposure to mosquitoes has not been evaluated and may not provide complete heartworm prevention.⁴

[‡]6 out of 8 dogs remained uninfected in the Simparica Trio group vs. 2 out of 8 dogs in the NexGard PLUS group.

[†]P=0.0316

[‡]Vs 98.1% efficacy for NexGard PLUS

In a head-to-head study, Simparica Trio® outperformed NexGard® PLUS against the drug resistant heartworm isolate ZoeLA.¹



The study assessed the efficacy of both parasiticides against the macrocyclic-lactone drug resistant heartworm isolate ZoeLA after 6 consecutive monthly doses.

Treatment	Mean Moxidectin Dose (Range)	Days of Treatment	Number of Dogs with Adult Worms*	Adult <i>D. immitis</i> Worm Counts			Number of Antigen Positive Dogs [§]	Number of Dogs with Microfilariae
				Individual Heartworm Counts	Geometric Mean [†]	Percentage Reduction [‡]		
Pet-Tabs (Placebo)	N/A	0, 30, 60, 90, 120, 150	8 of 8	26, 34, 35, 35, 36, 38, 42, 45	36 ^a	N/A	8 of 8	7 of 8
Simparica Trio	37.9 µg/kg (24.11 - 47.78)	0, 30, 60, 90, 120, 150	2 of 8	0, 0, 0, 0, 0, 0, 1, 1*	0.2 ^b	99.5%	1 of 8	0 of 8
NexGard PLUS	17.6 µg/kg (14.78 - 20)	0, 30, 60, 90, 120, 150	6 of 8	0, 0, 1, 1, 1, 1, 1, 1	0.7 ^c	98.1%	4 of 8	1 of 8

* Findings from necropsy examination.

† Geometric mean counts with different superscript letters are significantly different ($P < 0.05$).

- Simparica Trio or NexGard PLUS vs. Placebo: $P < 0.0001$

- Simparica Trio vs. NexGard PLUS: $P = 0.0316$

‡ Percent reduction compared to Placebo.

§ SNAP® Heartworm RT (IDEXX).

¶ Stunted female worm recovered from abdominal cavity.

INDICATIONS

Simparica Trio is indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment and control of roundworm (immature adult and adult *Toxocara canis* and adult *Toxascaris leonina*) and hookworm (L4, immature adult, and adult *Ancylostoma caninum* and adult *Uncinaria stenocephala*) infections. Simparica Trio kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment and prevention of flea infestations, the prevention of *Dipylidium caninum* (tapeworm) infections as a direct result of killing *Ctenocephalides felis* vector fleas on the treated dog, and the treatment and control of tick infestations with *Amblyomma americanum* (lone star tick), *Amblyomma maculatum* (Gulf Coast tick), *Dermacentor variabilis* (American dog tick), *Ixodes scapularis* (black-legged tick), *Rhipicephalus sanguineus* (brown dog tick), and *Haemaphysalis longicornis* (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica Trio is indicated for the prevention of *Borrelia burgdorferi* infections as a direct result of killing *Ixodes scapularis* vector ticks.

IMPORTANT SAFETY INFORMATION

Use with caution in dogs with a history of seizures. Simparica Trio contains sarolaner, a member of the isoxazoline class which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. See full Prescribing Information at [SimparicaTrioPI.com](https://www.simparicatrio.com).

References:

1. Data on file, Study A162R-US-23-D72, Zoetis Inc.
2. McTier TL, Six RH, Pullins A et al. 2019. Parasit Vectors. DOI:10.1186/s13071-019-3685-3
3. Myers JAE, Holzmer S, McCall JW, et al. 2022. Parasit Vectors. doi:https://doi.org/10.1186/s13071-022-05180-3
4. NexGard® PLUS [package insert].

NexGard® PLUS is a trademark of Boehringer Ingelheim Animal Health France, used under license. SNAP is a trademark of IDEXX.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2026 Zoetis Services. All rights reserved. STR-00896

zoetis